Oncology News | pharmaphorum

News

Myricx founders (l-r) Dr Andrew Bell, Dr Roberto Solari and Professor Ed Tate, with CEO Dr Robin Carr

Myricx raises £90m after pivot to ADCs for cancer

UK biotech Myricx Bio has tapped into the red-hot interest among investors for companies working on antibody-drug conjugates (ADCs) for cancer, raising £90 million ($115 million) in a first

News

Study finds GLP-1 drugs may cut obesity-related cancers

Potentially adding to a lengthening list of positive health benefits of GLP-1 agonist drugs, a new study has suggested they may also reduce the risk of a bevy of cancers associated with bei

News

Pieris loses Servier as partner for cancer immunotherapies

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern.

News

Histopathologic image of colonic carcinoid stained by hematoxylin and eosin.

Deep learning AI predicts response to cancer treatment

Artificial intelligence software developed by Pangea Biomed can predict the chances that a patient will respond to cancer treatment by looking at tumour histopathology images.

News

Roche’s TIGIT drug linked to worse outcomes in NSCLC trial

Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm for the programme just as there were signs that it was getting back on track after a series of disappo

News

Advantage J&J in multiple myeloma CAR-T tussle with BMS

Johnson & Johnson and partner Legend Biotech are celebrating a big win in their efforts to expand the use of CAR-T therapy Carvykti for multiple myeloma, after showing a survival benefi

Myricx raises £90m after pivot to ADCs for cancer

Study finds GLP-1 drugs may cut obesity-related cancers

Pieris loses Servier as partner for cancer immunotherapies

Deep learning AI predicts response to cancer treatment

Roche’s TIGIT drug linked to worse outcomes in NSCLC trial

Advantage J&J in multiple myeloma CAR-T tussle with BMS

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks